Anthem Blue Cross and Blue Shield | CommercialMay 1, 2023
Clinical Criteria updates for specialty pharmacy are available
Effective for dates of service on and after August 1, 2023, the following Clinical Criteria were developed and might result in services that were previously covered but may now be found to be not medically necessary.
For Anthem Blue Cross and Blue Shield and its affiliate HealthKeepers, Inc., prior authorization of these specialty pharmacy drugs will be managed by Anthem. Drugs used for the treatment of oncology will still require prior authorization by Carelon Medical Benefits Management, Inc.* This applies to members with Preferred Provider Organization (PPO), Anthem HealthKeepers (HMO), POS AdvantageOne, and Act Wise (CDH plans).
Access the Clinical Criteria document information at https://anthem.com/ms/pharmacyinformation/clinicalcriteria.html.
CC-0096 | Asparagine Specific Enzymes |
CC-0128 | Tecentriq (atezolizumab) |
CC-0131 | Besponsa (inotuzumab ozogamicin) |
CC-0233 | Rebyota (fecal microbiota, live – islm) |
* Carelon Medical Benefits Management, Inc. is an independent company providing utilization management services on behalf of the health plan.
VABCBS-CM-022599-23
PUBLICATIONS: May 2023 Provider News
To view this article online:
Or scan this QR code with your phone